[go: up one dir, main page]

RS60201B1 - Antigen vezujući molekuli koji sadrže trimer liganda familije tnf - Google Patents

Antigen vezujući molekuli koji sadrže trimer liganda familije tnf

Info

Publication number
RS60201B1
RS60201B1 RS20200473A RSP20200473A RS60201B1 RS 60201 B1 RS60201 B1 RS 60201B1 RS 20200473 A RS20200473 A RS 20200473A RS P20200473 A RSP20200473 A RS P20200473A RS 60201 B1 RS60201 B1 RS 60201B1
Authority
RS
Serbia
Prior art keywords
groove
protrusions
joint
base
insert
Prior art date
Application number
RS20200473A
Other languages
English (en)
Inventor
Maria Amann
Peter Bruenker
Christina Claus
Koller Claudia Ferrara
Sandra Grau-Richards
Christian Klein
Viktor Levitsky
Ekkehard Moessner
Joerg Thomas Regula
Pablo Umaña
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54695680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS60201(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of RS60201B1 publication Critical patent/RS60201B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Connection Of Plates (AREA)
  • Furniture Connections (AREA)

Description

ZGLOBNA VEZA ZA SPAJANJE DIJELOVA NAMJEŠTAJA U CJELII)!U
Oblast tehnike na koju se pronalazak odnosi
Pronalazak pripada oblasti namještaja i opšte tehnike.
Tehnički problem
Pronalazak rješava problem povezivanja dijelova na-mještaja, kao što su sjedalo, naslon, noge i slično u cjelinu.
Stanje tehnike
Zglobna veza bez spojnih sredstava - direktnim spa-janjem - do sada se ostvarivala tako što je umetak trpio el-astičnu deformaciju dok je utor bio krut i što je utor posje-dovao oslonačku ravan. Nedostatak ovog rješenja je u izlože-nosti umetka oštećenju odnosno njegovoj smanjenoj sposobnosti da preuzme silu.
Izlaganje suštine pronalaska
Suština pronalaska je da se kod zglobne veze bez spojnih sredstava, a koja se sastoji od umetka i utora, pojača čvrstoća umetka jer je umetak samim svojim položajem izložen silama. Novost pronalaska je u tome da utor, a ne umetak, trpi elastičnu deformaciju.
Prednost ovog rješenja vidi se pri postupku montaže, demontaže kao i pri manipulaciji dijelovima.
Kratak opis slika nacrta
Slika 1 predstavlja horizontalni presjek kroz zglob, Slika 2 predstavlja vertikalni presjek kroz zglob,
Slika 3 predstavlja aksonometrijski prikaz umetka.
i utora.
Detaljan opis pronalaska
Zglobna veza za spajanje dijelova namještaja u cjelinu sastoji se od umetka (2) i utora (3).
Umetak (2) je u obliku šupljeg<p>ravog kružnog valjka koji je bez jedne osnove a druga, nasuprotna osnova, je u obliku kupe kojoj je odsječen vrh a koja je uzdignuta iznad o-motača valjka.
Utor (3) je u obliku valjka koji je bez jedne osnove a čija kružna linija osnove na dva svoja mjesta ima, gledano iz središta osnove, konveksno izbočenje (4) stvoreno postepenim prelazom u obliku sinusoide. Konveksno izbočenje (4) se prosti-re duž čitave visine utora (3).
Kad umetak (2) gurnemo u utor (3) u smjeru uzdužne osi zgloba (l), a do ravni oslonca (5), dolazi do elastične deformacije utora (3). Elastična deformacija utora (3) stvara, si-lu naprezanja koja povezuje umetak ( 2) i utor (3) u cjelinu. Svrha kosine (6) jest da omogući ulaz umetka (2) u utor (3). Svrha izbočenje. (4) jest da omogući elastičnu deformaciju a svrha ravni oslonca (5),koja geometrijski pripada istoj ravni kao i kružna geometrijska osnova valjka umetka, jest da preuzme silu u smjeru uzdužne osi zgloba (1). Uzdužna os zgloba (1) upravna je na podnu ravan.
U slučajevima kad je pronalazak izložen sili ro-tacije oko uzdužne osi zgloba (l) pripadajući dijelovi namje-štaja povezuju se najmanje sa dva paralelno postavljena pronalaska.

Claims (8)

1. Zglobna veza za spajanje dijelova namještaja u cjelinu sastoji se od umetka (2) i utora (3), naznačena time, što umetak (2) koji posjeduje kosinu (6) ima oblik šupljeg pra-vog kružnog valjka koji je bez jedne osnove a druga, nasuprotna osnova, je u obliku kupe odsječenog vrba uzdignute iznad omot-ača valjka, dok utor (3) ima oblik, na jednoj strani osnove, šupljeg valjka čija kružna linija osnove posjeduje, glede-no iz središta osnove a duž čitave visine utora, dva konveksna iz-bočenja (4) stvorena postepenim prelazom u obliku sinusoide.
2. Zglobna veza prema zahtjevu -1, naznačena time, što utor (3) ima jedno izbočenje (4).
3. Zglobna veza prema zahtjevu 1, naznačena time, što utor (3) ima tri izbočenja (4).
4. Zglobna veza prema zahtjevu 1, naznačena time, što utor (3) ima četiri izbočenja (4),
5. Zglobna veza prema zahtjevu 1, naznačena time, što utor (3) ima pet izbočenja (4).
6. Zglobna veza prema zahtjevu 1, naznačena time, što utor (3) ima šest izbočenja (4).
7. Zglobna veza prema zahtjevu 1, naznačena time, što utor (3) ima sedam izbočenja (4).
8. Zglobna veza prema zahtjevu 1, naznačena time, što utor (3) ima osam izbočenja (4).
RS20200473A 2014-11-14 2015-11-13 Antigen vezujući molekuli koji sadrže trimer liganda familije tnf RS60201B1 (sr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14193260 2014-11-14
EP15183736 2015-09-03
EP15188142 2015-10-02
PCT/EP2015/076528 WO2016075278A1 (en) 2014-11-14 2015-11-13 Antigen binding molecules comprising a tnf family ligand trimer
EP15797922.0A EP3224275B1 (en) 2014-11-14 2015-11-13 Antigen binding molecules comprising a tnf family ligand trimer

Publications (1)

Publication Number Publication Date
RS60201B1 true RS60201B1 (sr) 2020-06-30

Family

ID=54695680

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20210600A RS61870B1 (sr) 2014-11-14 2015-11-13 Antigen vezujući molekuli koji sadrže trimer liganda iz tnf familije
RS20200473A RS60201B1 (sr) 2014-11-14 2015-11-13 Antigen vezujući molekuli koji sadrže trimer liganda familije tnf

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RS20210600A RS61870B1 (sr) 2014-11-14 2015-11-13 Antigen vezujući molekuli koji sadrže trimer liganda iz tnf familije

Country Status (29)

Country Link
US (6) US10392445B2 (sr)
EP (3) EP3224275B1 (sr)
JP (2) JP6873901B2 (sr)
KR (3) KR20250158074A (sr)
CN (4) CN114634570B (sr)
AU (3) AU2015345024B2 (sr)
CL (2) CL2017001000A1 (sr)
CO (1) CO2017003212A2 (sr)
CR (1) CR20170194A (sr)
DK (2) DK3489256T3 (sr)
EA (1) EA037557B1 (sr)
ES (2) ES2788979T3 (sr)
HR (2) HRP20200679T1 (sr)
HU (2) HUE054122T2 (sr)
IL (2) IL282922B (sr)
LT (2) LT3224275T (sr)
MA (2) MA40882B1 (sr)
MX (2) MX391388B (sr)
MY (1) MY191428A (sr)
PE (2) PE20170896A1 (sr)
PH (1) PH12017500892B1 (sr)
PL (2) PL3489256T3 (sr)
PT (1) PT3224275T (sr)
RS (2) RS61870B1 (sr)
SG (1) SG11201703597TA (sr)
SI (2) SI3224275T1 (sr)
TW (2) TWI757803B (sr)
UA (1) UA125577C2 (sr)
WO (1) WO2016075278A1 (sr)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
EP2961771B1 (en) 2013-02-26 2020-01-01 Roche Glycart AG Bispecific t cell activating antigen binding molecules specific to cd3 and cea
BR112015024752A2 (pt) 2013-03-27 2017-07-18 Cedars Sinai Medical Center mitigação e reversão da fibrose e inflamação através da inibição da função de tl1a e vias de sinalização relacionadas
WO2015010108A1 (en) 2013-07-19 2015-01-22 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
DK3489256T3 (da) 2014-11-14 2021-05-25 Hoffmann La Roche Antigenbindende molekyler omfattende en TNF-familieligandtrimer
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
WO2016156291A1 (en) 2015-03-31 2016-10-06 F. Hoffmann-La Roche Ag Antigen binding molecules comprising a trimeric tnf family ligand
AR106188A1 (es) * 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
MY192202A (en) 2015-10-02 2022-08-06 Hoffmann La Roche Bispecific antibodies specific for pd1 and tim3
EP3356403A2 (en) 2015-10-02 2018-08-08 H. Hoffnabb-La Roche Ag Bispecific antibodies specific for a costimulatory tnf receptor
CN107849137B (zh) * 2015-10-02 2021-11-26 豪夫迈·罗氏有限公司 双特异性抗ceaxcd3 t细胞活化性抗原结合分子
WO2017055314A1 (en) * 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
JP6918789B2 (ja) * 2015-10-02 2021-08-11 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 高親和性を有する抗ヒトｃｄｃ１９抗体
WO2017083525A1 (en) 2015-11-11 2017-05-18 Opi Vi- Ip Holdco Llc Composition and methods for anti-tnfr2 antibodies
EP3400246B1 (en) 2016-01-08 2020-10-21 H. Hoffnabb-La Roche Ag Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
JP7082945B2 (ja) 2016-03-17 2022-06-09 シーダーズ―シナイ メディカル センター Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法
CN109071652B (zh) 2016-05-11 2022-09-23 豪夫迈·罗氏有限公司 包含tnf家族配体三聚体和生腱蛋白结合模块的抗原结合分子
EP3243836A1 (en) * 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminally fused tnf family ligand trimer-containing antigen binding molecules
EP3243832A1 (en) * 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
WO2018073365A1 (en) 2016-10-19 2018-04-26 F. Hoffmann-La Roche Ag Method for producing an immunoconjugate
WO2018081074A1 (en) 2016-10-26 2018-05-03 Cedars-Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies
CN117752798A (zh) * 2016-12-19 2024-03-26 豪夫迈·罗氏有限公司 用靶向性4-1bb(cd137)激动剂的组合疗法
EP3559034B1 (en) * 2016-12-20 2020-12-02 H. Hoffnabb-La Roche Ag Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
MA47200A (fr) 2017-01-03 2019-11-13 Hoffmann La Roche Molécules bispécifiques de liaison à l'antigène comprenant un clone 20h4.9 anti-4-1bb
CA3047708A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A sirpalpha-41bbl fusion protein and methods of use thereof
CN110536693B (zh) 2017-01-05 2023-12-22 卡尔医学有限公司 Pd1-41bbl融合蛋白及使用其的方法
US11566060B2 (en) 2017-01-05 2023-01-31 Kahr Medical Ltd. PD1-CD70 fusion protein and methods of use thereof
US20200291089A1 (en) * 2017-02-16 2020-09-17 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
EP3601345A1 (en) 2017-03-29 2020-02-05 H. Hoffnabb-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
CN110382542B (zh) 2017-03-29 2023-06-09 豪夫迈·罗氏有限公司 针对共刺激性tnf受体的双特异性抗原结合分子
WO2018184964A1 (en) 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
EP3606956B1 (en) 2017-04-04 2024-07-31 F. Hoffmann-La Roche AG Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap
EP3606955B1 (en) 2017-04-05 2024-11-06 F. Hoffmann-La Roche AG Bispecific antibodies specifically binding to pd1 and lag3
EP3615564A1 (en) * 2017-04-24 2020-03-04 Alexion Pharmaceuticals, Inc. Antibody immune cell inhibitor fusion proteins
AU2018281306B2 (en) 2017-06-07 2025-04-17 Spark Therapeutics, Inc. Enhancing agents for improved cell transfection and/or rAAV vector production
CN111246884A (zh) * 2017-11-01 2020-06-05 豪夫迈·罗氏有限公司 新颖的含有tnf家族配体三聚体的抗原结合分子
EP3502140A1 (en) * 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
KR102471868B1 (ko) * 2018-01-15 2022-11-30 아이-맵 바이오파마 유에스 리미티드 변형된 Cκ 및 CH1 도메인
TWI841551B (zh) * 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 使用靶向4-1bb (cd137)之促效劑的組合療法
AU2019236372B2 (en) * 2018-03-13 2024-06-20 F. Hoffmann-La Roche Ag Therapeutic combination of 4-1 BB agonists with anti-CD20 antibodies
SG11202007961QA (en) 2018-04-13 2020-09-29 Hoffmann La Roche Her2-targeting antigen binding molecules comprising 4-1bbl
JP7332627B2 (ja) 2018-04-25 2023-08-23 プロメテウス バイオサイエンシーズ，インク． 最適化された抗ｔｌ１ａ抗体
WO2020007817A1 (en) 2018-07-04 2020-01-09 F. Hoffmann-La Roche Ag Novel bispecific agonistic 4-1bb antigen binding molecules
US12134638B2 (en) * 2018-07-11 2024-11-05 Kahr Medical Ltd. SIRPalpha-4-1BBL variant fusion protein and methods of use thereof
MX2021000047A (es) * 2018-07-11 2021-05-12 Kahr Medical Ltd Proteina de fusion variante pd1-4-1bbl y procedimientos de uso de la misma.
MX2021003548A (es) 2018-10-01 2021-05-27 Hoffmann La Roche Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap.
TWI839395B (zh) * 2018-10-09 2024-04-21 瑞士商Ｎｕｍａｂ治療公司 靶向cd137的抗體及其使用方法
US11608376B2 (en) 2018-12-21 2023-03-21 Hoffmann-La Roche Inc. Tumor-targeted agonistic CD28 antigen binding molecules
UY38739A (es) 2019-06-04 2020-12-31 Molecular Partners Ag Proteínas multiespecíficas
BR112021025022A2 (pt) * 2019-06-12 2022-02-22 Obsidian Therapeutics Inc Composições de ca2 e métodos para regulação ajustáveis
KR20220025848A (ko) 2019-06-26 2022-03-03 에프. 호프만-라 로슈 아게 Cea 및 4-1bbl에 결합하는 항체의 융합
CN117821393A (zh) 2019-06-26 2024-04-05 豪夫迈·罗氏有限公司 具有sirt-1基因敲除的哺乳动物细胞系
AR119382A1 (es) 2019-07-12 2021-12-15 Hoffmann La Roche Anticuerpos de pre-direccionamiento y métodos de uso
IL292419A (en) 2019-10-24 2022-06-01 Prometheus Biosciences Inc Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
CN114929734A (zh) * 2020-01-09 2022-08-19 豪夫迈·罗氏有限公司 新型含有4-1bbl三聚体的抗原结合分子
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
CN113234139A (zh) * 2020-04-17 2021-08-10 百奥赛图江苏基因生物技术有限公司 Tnfsf9基因人源化的非人动物及其构建方法和应用
WO2021229103A2 (en) 2020-05-15 2021-11-18 Apogenix Ag Multi-specific immune modulators
IL298402A (en) 2020-06-19 2023-01-01 Hoffmann La Roche Antibodies that bind to CD3 and CD19
KR20230037578A (ko) 2020-07-10 2023-03-16 에프. 호프만-라 로슈 아게 암 세포에 결합하고 방사성 핵종을 상기 세포로 표적화하는 항체
BR112023001209A2 (pt) * 2020-07-24 2023-02-14 Hoffmann La Roche Método para produzir um polipeptídeo de fusão-anticorpo-multímero
US20240082437A1 (en) 2021-01-12 2024-03-14 Hoffmann-La Roche Inc. Split antibodies which bind to cancer cells and target radionuclides to said cells
US20240173442A1 (en) 2021-01-13 2024-05-30 Hoffmann-La Roche Inc. Combination therapy
AU2022231874A1 (en) 2021-03-09 2023-07-27 F. Hoffmann-La Roche Ag Combination therapy of pd-1-targeted il-2 variant immunoconjugates and fap/4-1bb binding molecules
WO2022243261A1 (en) 2021-05-19 2022-11-24 F. Hoffmann-La Roche Ag Agonistic cd40 antigen binding molecules targeting cea
TW202307003A (zh) * 2021-05-21 2023-02-16 英屬開曼群島商百濟神州有限公司 抗ｃｅａ和抗ｃｄ１３７多特異性抗體及其使用方法
TW202317619A (zh) * 2021-06-01 2023-05-01 美商健生生物科技公司 針對抗cd79b抗體的抗獨特型抗體
EP4148067A1 (en) * 2021-09-08 2023-03-15 F. Hoffmann-La Roche AG Method for the expression of an antibody-multimer-fusion
JP2024540174A (ja) 2021-11-01 2024-10-31 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｈｌａ－ａ２／ｗｔ１×ｃｄ３二重特異性抗体および４－１ｂｂ（ｃｄ１３７）アゴニストを用いたがんの治療
WO2023088889A1 (en) 2021-11-16 2023-05-25 Apogenix Ag CD137 ligands
WO2023088876A1 (en) 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators
EP4448560A1 (en) 2021-12-14 2024-10-23 F. Hoffmann-La Roche AG Treatment of cancer using a hla-a2/mage-a4 x cd3 bispecific antibody and a 4-1bb (cd137) agonist
CN114349869B (zh) * 2021-12-20 2023-09-26 上海恩凯细胞技术有限公司 一种双特异性的nk细胞激动剂及制备方法和应用
CN114426585B (zh) * 2022-02-15 2023-10-03 广东香雪干细胞再生医学科技有限公司 融合蛋白及其表达细胞株与应用
CN116640226B (zh) * 2022-04-02 2024-04-26 广东东阳光药业股份有限公司 一种抑制宿主抗外源免疫细胞hvg反应的嵌合受体
CN114805564B (zh) * 2022-06-10 2023-06-06 郑州大学 特异性识别SARS-CoV-2 S蛋白NTD区域的单克隆抗体及应用
KR20250067128A (ko) 2022-09-15 2025-05-14 아비디큐어 아이피 비.브이. Nk 세포의 종양-표적화를 위한 다중특이적 항원 결합 단백질 및 이의 용도
CN120152989A (zh) 2022-11-03 2025-06-13 豪夫迈·罗氏有限公司 抗cd19/抗cd28双特异性抗体的组合疗法
CN116574189A (zh) 2023-01-30 2023-08-11 北京智仁美博生物科技有限公司 针对人il-36r和/或人il-1r3的多种抗体及其用途
CN120826234A (zh) 2023-03-06 2025-10-21 豪夫迈·罗氏有限公司 抗EGFRvIII/抗CD3抗体与肿瘤靶向性4-1BB激动剂的组合疗法
EP4680638A1 (en) 2023-03-13 2026-01-21 F. Hoffmann-La Roche AG Treatment of cancer using an anti-hla-g/anti-cd3 bispecific antibody and a 4-1bb (cd137) agonist
CN118894934A (zh) 2023-05-05 2024-11-05 北京智仁美博生物科技有限公司 抗人il-15的抗体及其用途
WO2025113643A1 (en) 2023-12-01 2025-06-05 Gilead Sciences Inc. Anti-fap-light fusion protein and use thereof
WO2025140212A1 (en) * 2023-12-26 2025-07-03 Laekna Therapeutics Shanghai Co., Ltd. Multispecific binding agents comprising anti-fibroblast activation protein (fap) antibodies and one or more monovalent ligand traps and uses thereof
WO2025191137A1 (en) * 2024-03-15 2025-09-18 Avidicure Ip B.V. Conjugates of trop2-specific antigen binding proteins and cytokines
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1096187A (en) 1977-04-18 1981-02-24 Souhei Monden Ornament adapted to be fixed by permanent magnets
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
ATE503496T1 (de) 1992-02-06 2011-04-15 Novartis Vaccines & Diagnostic Biosynthetisches bindeprotein für tumormarker
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
DK2857516T3 (en) 2000-04-11 2017-08-07 Genentech Inc Multivalent antibodies and uses thereof
CA2421447C (en) 2000-09-08 2012-05-08 Universitat Zurich Collections of repeat proteins comprising repeat modules
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
CA2503697A1 (en) 2002-10-29 2004-05-13 Borean Pharma A/S Trimeric binding proteins for trimeric cytokines
AU2004210088A1 (en) * 2003-02-06 2004-08-19 Micromet Ag Trimeric polypeptide construct to induce an enduring T cell response
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
ATE416190T1 (de) 2003-07-04 2008-12-15 Affibody Ab Polypeptide mit bindungsaffinität für her2
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
DK2380910T3 (en) 2003-11-05 2015-10-19 Roche Glycart Ag Antigen binding molecules with increased Fc receptor binding affinity and effector function
JP5006651B2 (ja) 2003-12-05 2012-08-22 ブリストル−マイヤーズ スクウィブ カンパニー ２型血管内皮増殖因子受容体の阻害剤
MXPA06011199A (es) 2004-03-31 2007-04-16 Genentech Inc Anticuerpos anti-tgf-beta humanizados.
PL1737891T3 (pl) 2004-04-13 2013-08-30 Hoffmann La Roche Przeciwciała przeciw selektynie p
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
NZ553500A (en) 2004-09-23 2009-11-27 Genentech Inc Genentech Inc Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2011265482B2 (en) * 2005-05-06 2013-08-29 Providence Health & Services - Oregon Trimeric OX40L-immunoglobulin fusion protein and methods of use
AU2013263717B2 (en) 2005-05-06 2016-05-19 Providence Health & Services - Oregon Trimeric OX40L-immunoglobulin fusion protein and methods of use
EP1736482A1 (en) 2005-06-20 2006-12-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Recombinant trimeric 4-1BBL
DE102005036542A1 (de) 2005-08-03 2007-02-08 Universität Stuttgart CTL-Prodrug
HRP20140331T1 (hr) 2006-08-14 2014-05-09 Xencor, Inc. Optimizirana antitijela usmjerena na cd19
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety
EP2009022A1 (en) 2007-06-26 2008-12-31 Apogenix GmbH Trimeric death ligands with enhanced activity (tenascin)
GB0718843D0 (en) 2007-09-26 2007-11-07 Cancer Rec Tech Ltd Materials and methods relating to modifying the binding of antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
HRP20150425T1 (hr) * 2008-07-21 2015-06-05 Apogenix Gmbh Tnf sf jednolanäśane molekule
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
JP5764127B2 (ja) 2009-08-17 2015-08-12 ロシュ グリクアート アーゲー 標的化イムノコンジュゲート
HRP20141032T1 (hr) 2009-09-29 2015-01-30 Roche Glycart Ag Bispecifiäśna agonistiäśka protutijela receptora smrtnosti
PL2542590T5 (pl) 2010-03-05 2020-08-10 The Johns Hopkins University Kompozycje i sposoby dla ukierunkowanych immunomodulatorowych przeciwciał i białek fuzyjnych
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
US8552024B2 (en) 2010-08-13 2013-10-08 Hoffman-La Roche Inc. Azacyclic compounds
KR101780131B1 (ko) 2010-08-13 2017-09-19 로슈 글리카트 아게 항-fap 항체 및 이의 사용 방법
TWI666027B (zh) 2011-02-10 2019-07-21 羅齊克雷雅公司 突變介白素-２多肽
KR101614195B1 (ko) 2011-03-29 2016-04-20 로슈 글리카트 아게 항체 Fc 변이체
JP6047142B2 (ja) 2011-04-01 2016-12-21 ウニヴェルズィテート シュトゥットガルト 抗体結合ドメインを有する組換えｔｎｆリガンドファミリーメンバーポリペプチドおよびそれらの使用
JP2013055204A (ja) 2011-09-02 2013-03-21 Toshiba Corp 半導体記憶装置
CA2947354C (en) 2012-04-30 2024-03-19 Biocon Limited Targeted/immunomodulatory fusion proteins and methods for making same
EP2882774B1 (en) 2012-08-08 2018-10-03 Roche Glycart AG Interleukin-10 fusion proteins and uses thereof
EP2948475A2 (en) * 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
EP2961771B1 (en) * 2013-02-26 2020-01-01 Roche Glycart AG Bispecific t cell activating antigen binding molecules specific to cd3 and cea
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
EP2994487B1 (en) 2013-05-07 2019-10-09 F.Hoffmann-La Roche Ag Trimeric antigen binding molecules
JP2017506075A (ja) 2014-02-06 2017-03-02 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト インターロイキン−１０イムノコンジュゲート
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
WO2015183902A1 (en) 2014-05-29 2015-12-03 Medimmune, Llc Ox40l fusion proteins and uses thereof
AP2016009586A0 (en) 2014-05-29 2016-11-30 Macrogenics Inc Tri-specific binding molecules and methods of use thereof
DK3489256T3 (da) 2014-11-14 2021-05-25 Hoffmann La Roche Antigenbindende molekyler omfattende en TNF-familieligandtrimer
WO2016156291A1 (en) 2015-03-31 2016-10-06 F. Hoffmann-La Roche Ag Antigen binding molecules comprising a trimeric tnf family ligand
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
WO2017055539A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Multispecific antibodies
WO2017055314A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
EP3356403A2 (en) 2015-10-02 2018-08-08 H. Hoffnabb-La Roche Ag Bispecific antibodies specific for a costimulatory tnf receptor
JP6918789B2 (ja) 2015-10-02 2021-08-11 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 高親和性を有する抗ヒトｃｄｃ１９抗体
MY193013A (en) 2015-10-07 2022-09-22 Hoffmann La Roche Bispecific antibodies with tetravalency for a costimulatory tnf receptor
EP3231813A1 (en) 2016-03-29 2017-10-18 F. Hoffmann-La Roche AG Trimeric costimulatory tnf family ligand-containing antigen binding molecules
CN109071652B (zh) 2016-05-11 2022-09-23 豪夫迈·罗氏有限公司 包含tnf家族配体三聚体和生腱蛋白结合模块的抗原结合分子
EP3243836A1 (en) 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminally fused tnf family ligand trimer-containing antigen binding molecules
EP3243832A1 (en) 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
CN109791067B (zh) 2016-07-08 2021-09-07 豪夫迈·罗氏有限公司 用于处理实验室样品的装置、实验室自动化系统和用于对实验室样品进行移液的方法
CN117752798A (zh) 2016-12-19 2024-03-26 豪夫迈·罗氏有限公司 用靶向性4-1bb(cd137)激动剂的组合疗法
EP3559034B1 (en) 2016-12-20 2020-12-02 H. Hoffnabb-La Roche Ag Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
MA47200A (fr) 2017-01-03 2019-11-13 Hoffmann La Roche Molécules bispécifiques de liaison à l'antigène comprenant un clone 20h4.9 anti-4-1bb
CN110382542B (zh) 2017-03-29 2023-06-09 豪夫迈·罗氏有限公司 针对共刺激性tnf受体的双特异性抗原结合分子
EP3601345A1 (en) 2017-03-29 2020-02-05 H. Hoffnabb-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
EP3606956B1 (en) 2017-04-04 2024-07-31 F. Hoffmann-La Roche AG Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap
MA50505A (fr) 2017-11-01 2020-09-09 Hoffmann La Roche Anticorps 2 + 1 bispécifiques (contorsbodies)
CN111246884A (zh) 2017-11-01 2020-06-05 豪夫迈·罗氏有限公司 新颖的含有tnf家族配体三聚体的抗原结合分子
AU2019236372B2 (en) 2018-03-13 2024-06-20 F. Hoffmann-La Roche Ag Therapeutic combination of 4-1 BB agonists with anti-CD20 antibodies
TWI841551B (zh) 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 使用靶向4-1bb (cd137)之促效劑的組合療法
SG11202007961QA (en) 2018-04-13 2020-09-29 Hoffmann La Roche Her2-targeting antigen binding molecules comprising 4-1bbl
WO2020007817A1 (en) 2018-07-04 2020-01-09 F. Hoffmann-La Roche Ag Novel bispecific agonistic 4-1bb antigen binding molecules
MX2021003548A (es) 2018-10-01 2021-05-27 Hoffmann La Roche Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap.
CN112654641A (zh) 2018-10-01 2021-04-13 豪夫迈·罗氏有限公司 具有与cd40的三价结合的双特异性抗原结合分子
CN113677403B (zh) 2019-04-12 2024-12-27 豪夫迈·罗氏有限公司 包含脂质运载蛋白突变蛋白的双特异性抗原结合分子
KR20220025848A (ko) 2019-06-26 2022-03-03 에프. 호프만-라 로슈 아게 Cea 및 4-1bbl에 결합하는 항체의 융합
CN114929734A (zh) 2020-01-09 2022-08-19 豪夫迈·罗氏有限公司 新型含有4-1bbl三聚体的抗原结合分子
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap

Also Published As

Publication number Publication date
CN113372434B (zh) 2024-06-04
TWI757803B (zh) 2022-03-11
LT3224275T (lt) 2020-05-25
NZ767672A (en) 2024-02-23
ES2788979T3 (es) 2020-10-23
IL282922A (en) 2021-06-30
CL2017001000A1 (es) 2018-01-12
HRP20200679T1 (hr) 2020-07-24
IL251317A0 (en) 2017-05-29
KR102588377B1 (ko) 2023-10-12
CO2017003212A2 (es) 2017-09-20
DK3489256T3 (da) 2021-05-25
MA40882A (fr) 2017-10-04
JP6873901B2 (ja) 2021-05-19
EP3489256B1 (en) 2021-03-17
AU2022201144A1 (en) 2022-03-17
CN113372434A (zh) 2021-09-10
US20220259326A1 (en) 2022-08-18
AU2015345024B2 (en) 2020-10-15
EP3738609B1 (en) 2025-06-18
PH12017500892A1 (en) 2017-11-06
AU2022201144B2 (en) 2025-03-06
US20200247904A1 (en) 2020-08-06
US10392445B2 (en) 2019-08-27
US11306154B2 (en) 2022-04-19
IL251317B (en) 2021-05-31
JP2021097674A (ja) 2021-07-01
TW201629094A (zh) 2016-08-16
MX391388B (es) 2025-03-21
JP7184938B2 (ja) 2022-12-06
SI3489256T1 (sl) 2021-08-31
TWI713474B (zh) 2020-12-21
EA201791057A1 (ru) 2017-10-31
CN108064237A (zh) 2018-05-22
US20160200833A1 (en) 2016-07-14
EP3224275B1 (en) 2020-03-04
CN114634570A (zh) 2022-06-17
AU2015345024A1 (en) 2017-04-20
CL2019003728A1 (es) 2020-07-17
NZ767674A (en) 2024-07-05
MX2020012798A (es) 2022-04-07
TW202041527A (zh) 2020-11-16
AU2020264337A1 (en) 2021-01-28
PL3489256T3 (pl) 2021-08-23
CA2963718A1 (en) 2016-05-19
HK1255482A1 (zh) 2019-08-16
PT3224275T (pt) 2020-05-04
MA53242A (fr) 2021-06-23
EP3738609A1 (en) 2020-11-18
BR112017009006A2 (pt) 2018-04-10
US20190382507A1 (en) 2019-12-19
PH12017500892B1 (en) 2023-08-18
HRP20210739T1 (hr) 2021-06-25
PE20221909A1 (es) 2022-12-23
MX2017006250A (es) 2017-11-17
AU2020264337B2 (en) 2021-12-02
DK3224275T3 (da) 2020-05-04
EA037557B1 (ru) 2021-04-14
EP3738609C0 (en) 2025-06-18
RS61870B1 (sr) 2021-06-30
KR20250158074A (ko) 2025-11-05
KR20170085552A (ko) 2017-07-24
NZ730933A (en) 2024-02-23
US20220259327A1 (en) 2022-08-18
PL3224275T3 (pl) 2020-09-07
UA125577C2 (uk) 2022-04-27
EP3489256A1 (en) 2019-05-29
SI3224275T1 (sl) 2020-07-31
LT3489256T (lt) 2021-06-10
CN120574325A (zh) 2025-09-02
KR102877243B1 (ko) 2025-10-29
MA40882B1 (fr) 2020-05-29
CN114634570B (zh) 2025-05-06
US20250101135A1 (en) 2025-03-27
HUE049982T2 (hu) 2020-11-30
US12441812B2 (en) 2025-10-14
EP3224275A1 (en) 2017-10-04
CN108064237B (zh) 2022-02-11
WO2016075278A1 (en) 2016-05-19
US11267903B2 (en) 2022-03-08
PE20170896A1 (es) 2017-07-12
ES2871045T3 (es) 2021-10-28
KR20230146133A (ko) 2023-10-18
MY191428A (en) 2022-06-27
SG11201703597TA (en) 2017-06-29
MX380253B (es) 2025-03-12
CR20170194A (es) 2017-07-10
HUE054122T2 (hu) 2021-08-30
IL282922B (en) 2022-08-01
JP2018503356A (ja) 2018-02-08

Similar Documents

Publication Publication Date Title
RS60201B1 (sr) Antigen vezujući molekuli koji sadrže trimer liganda familije tnf
CN204060131U (zh) 一种帐篷架顶部连接结构
IL258442A (en) Composition comprising a mixture of molecules extracted from chrysanthellum indicum, cynara scolymus and lycium barbarum and use to act on carbohydrate and/or fat metabolism
USD726473S1 (en) End frame for a bench
ES2539551R1 (es) Sistema de brazo universal
FR3045707B1 (fr) Connecteur pour assembler deux troncons de colonne montante avec bague de verrouillage externe et pions demontables
HRP20251243T1 (hr) Spojni element za spajanje profilnih elemenata
JP2016514566A5 (sr)
Chernov et al. A shape calculus based method for a transmission problem with a random interface
CN202739329U (zh) 一种可自由升降的课桌椅腿
PE20151177A1 (es) Conjunto de mesa de nivelacion segmentada y barra de contacto, y metodos en refinamiento hidrometalurgico
CN205144132U (zh) 一种服装挂架
CN104358401B (zh) 一种盘式脚手架
CN204105358U (zh) 一种拼接凳
JP2017070441A5 (sr)
CN104720414B (zh) 一种组装式椅梯
KR101405035B1 (ko) 석쇠
CN205547950U (zh) 五腿凳子
CN206119732U (zh) 一种新型折叠椅
CN205048081U (zh) 一种医用三通连接支架
CN203790267U (zh) 一种按摩椅
CN204383832U (zh) 可拆式封口棒
CN204040617U (zh) 一种帐篷架顶部连接结构
Azmi Editor in Chief word...
CN104358780B (zh) 一种滑动组合连接件